Search
for
Sort by
Research 601–630 of 1000+
- An essential role for <i>Rxrα</i> in the development of Th2 responses
- LB1777 A novel ex vivo model of human hair follicle immune privilege collapse reveals the potential of farudodstat, a DHODH inhibitor, as a therapeutic for alopecia areata treatment
- 014 Tyrosine Kinase 2 Inhibition Ameliorates the Phenotype of Lesional Alopecia Areata Scalp Skin Ex Vivo, and Reverses the Induction of Human Alopecia Areata in a Humanized Mouse Model
- IL-15 Prolongs Anagen, Stimulates Proliferation, and Suppresses Apoptosis in the Hair Matrix of Human Scalp Hair Follicles
- 0935 Unravelling the role of JAK3/TEC kinase signalling with ritlecitinib in alopecia areata lesional skin and alopecia areata-induced human hair follicles ex vivo
- Which is the ideal JAK inhibitor for alopecia areata – Baricitinib, tofacitinib, ritlecitinib or ifidancitinib - Revisiting the immunomechanisms of the JAK pathway
- The expression of inducible nitric oxide synthase (iNOS) in the testis and epididymis of rats with a dihydrotestosterone (DHT) deficiency
- SOCS1 and SOCS3 as key checkpoint molecules in the immune responses associated to skin inflammation and malignant transformation
- 331 An open label clinical trial of the JAK inhibitor tofacitinib for alopecia areata
- Carotid Intima Media Thickness Measurement in Alopecia Areata Patients
- Developing Human Skin Contains Lymphocytes Demonstrating a Memory Signature
- Efficacy and safety of ritlecitinib in Asian patients with alopecia areata: A subgroup analysis of the ALLEGRO phase 2b/3 trial
- 90 Exploring the therapeutic potential of DHODH inhibitor farudodstat for alopecia areata treatment in a novel ex vivo model of human hair follicle immune privilege collapse
- 808 Lichen planus single cell and spatial profiling of cutaneous lichen planus treated with baricitinib
- ISIDLB1777 - A novel ex vivo model of human hair follicle immune privilege collapse reveals the potential of farudodstat, a DHODH inhibitor, as a therapeutic for alopecia areata treatment
- Drug repurposing: A novel strategy to target cancer stem cells and therapeutic resistance
- Involvement of the Edar Signaling in the Control of Hair Follicle Involution (Catagen)
- GENETIC CONTROL OF CYTOKINES
- Under Development JAK Inhibitors for Dermatologic Diseases
- Adverse Reactions to Biologic Medications Used in Allergy and Immunology Diseases
- Novel Janus Kinase Inhibitors in the Treatment of Dermatologic Conditions
- ILC3s as central regulators of mucosal homeostasis and disease pathogenesis (Review)
- Melatonin in Dermatology
- Chemokine C-C Motif Ligand 7 (CCL7), a Biomarker of Atherosclerosis, Is Associated with the Severity of Alopecia Areata: A Preliminary Study
- AIRE Deficiency Leads to the Development of Alopecia Areata‒Like Lesions in Mice
- Immortalized human hair follicle-derived mesenchymal-like stromal cells for the long-term production of scalable Immunomodulatory and regenerative secretome
- 320 An open label clinical trial of Abatacept (CTLA4-Ig) for alopecia areata
- Possible Involvement of Skin‐Resident Memory T Cells in Refractory Chronic Alopecia Areata
- 0037 Inflammatory implications in female pattern hair loss: unraveling B cell-related immune activation through comparative transcriptome profiling
- Modulating immune responses in alopecia: therapeutic insights and potential targets of antisense oligonucleotides